

David M Euhus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6143514/publications.pdf>

Version: 2024-02-01

51
papers

1,630
citations

331670

21
h-index

302126

39
g-index

51
all docs

51
docs citations

51
times ranked

2600
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3025-3031.	1.5	184
2	Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2012, 30, 2844-2852.	1.6	179
3	Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO. <i>Journal of the National Cancer Institute</i> , 2002, 94, 844-851.	6.3	140
4	Axillary Node Interventions in Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1385.	7.4	133
5	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 751-758.	1.6	110
6	Delays in Time to Treatment and Survival Impact in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 291-296.	1.5	90
7	DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1051-1059.	2.5	76
8	The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. <i>Genetics in Medicine</i> , 2014, 16, 407-412.	2.4	67
9	Experience with Seed Localization for Nonpalpable Breast Lesions in a Public Health Care System. <i>Annals of Surgical Oncology</i> , 2010, 17, 3241-3246.	1.5	60
10	Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 196-205.e2.	0.8	57
11	Surgeon Re-Excision Rates after Breast-Conserving Surgery: A Measure of Low-Value Care. <i>Journal of the American College of Surgeons</i> , 2019, 228, 504-512.e2.	0.5	52
12	Loss of Heterozygosity in Benign Breast Epithelium in Relation to Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2002, 94, 858-860.	6.3	40
13	Survival and Disease Recurrence Rates among Breast Cancer Patients following Mastectomy with or without Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 169e-177e.	1.4	33
14	Atypia and DNA Methylation in Nipple Duct Lavage in Relation to Predicted Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1812-1821.	2.5	31
15	Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1880-1885.	1.5	29
16	Genetic Predisposition Syndromes and Their Management. <i>Surgical Clinics of North America</i> , 2013, 93, 341-362.	1.5	26
17	Estrogen Replacement Therapy After Breast Cancer: A 12-Year Follow-Up. <i>Annals of Surgical Oncology</i> , 2001, 8, 828-832.	1.5	25
18	Breast Cancer Screening. <i>Surgical Clinics of North America</i> , 2015, 95, 991-1011.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. <i>Human Pathology</i> , 2014, 45, 249-258.	2.0	22
20	A comparison of trends in operative approach and postoperative outcomes for colorectal cancer surgery. <i>Journal of Surgical Research</i> , 2017, 208, 111-120.	1.6	22
21	The Use of Tumescent Technique in Mastectomy and Related Complications. <i>Plastic and Reconstructive Surgery</i> , 2019, 143, 39-48.	1.4	22
22	Germline Genetic Testing: What the Breast Surgeon Needs to Know. <i>Annals of Surgical Oncology</i> , 2019, 26, 2184-2190.	1.5	19
23	Genetic Testing Today. <i>Annals of Surgical Oncology</i> , 2014, 21, 3209-3215.	1.5	16
24	Use of archival fine-needle aspirates for the allelotyping of tumors. , 1999, 87, 372-379.		15
25	Tamoxifen Downregulates <i>Ets</i> Oncogene Family Members <i>ETV4</i> and <i>ETV5</i> in Benign Breast Tissue: Implications for Durable Risk Reduction. <i>Cancer Prevention Research</i> , 2011, 4, 1852-1862.	1.5	15
26	Invasive Breast Cancer Preferably and Predominantly Occurs at the Interface Between Fibroglandular and Adipose Tissue. <i>Clinical Breast Cancer</i> , 2017, 17, e11-e18.	2.4	15
27	Risk Modeling in Breast Cancer. <i>Breast Journal</i> , 2004, 10, S10-S12.	1.0	12
28	Validating the performance of the mammary sentinel lymph node team. <i>Journal of Surgical Oncology</i> , 2002, 79, 209-215.	1.7	11
29	Breast Cancer Prevention. <i>Breast Journal</i> , 2015, 21, 76-81.	1.0	11
30	Change in health-related quality of life in older women after diagnosis of a small breast cancer. <i>Cancer</i> , 2019, 125, 1807-1814.	4.1	11
31	Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1 / 2 Mutation Carriers in Underserved Populations. <i>EBioMedicine</i> , 2015, 2, 1827-1833.	6.1	10
32	Managing the Breast in Patients Who Test Positive for Hereditary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1738-1744.	1.5	9
33	Genetic Factors in the Locoregional Management of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2220-2229.	1.6	9
34	Are Axillary Lymph Nodes Still Relevant in Breast Cancer ?. <i>Annals of Surgical Oncology</i> , 2014, 21, 4051-4053.	1.5	7
35	Genetic Ancestry using Mitochondrial DNA in patients with Triple-negative breast cancer (GAMiT) Tj ETQq1 1 0.784314 rgBJ /Overl	4.1	7
36	Cytokeratin Staining and Other Sentinel Node Controversies. <i>Clinical Breast Cancer</i> , 2003, 4, S49-S54.	2.4	5

#	ARTICLE	IF	CITATIONS
37	New insights into the prevention and treatment of familial breast cancer. Journal of Surgical Oncology, 2011, 103, 294-298.	1.7	5
38	New Insights into the Surgical Management of Breast Cancer. Seminars in Radiation Oncology, 2016, 26, 25-36.	2.2	5
39	Risk-Reducing Mastectomy for BRCA Gene Mutation Carriers. Annals of Surgical Oncology, 2015, 22, 2807-2809.	1.5	4
40	Breast cancer progression when definitive surgery is delayed. Breast Journal, 2021, 27, 307-313.	1.0	4
41	A model for predicting individualized absolute risk of contralateral breast cancer.. Journal of Clinical Oncology, 2016, 34, 1567-1567.	1.6	4
42	Why Breast Cancer Risk Models Fail: The Case of Lobular Carcinoma In Situ. Annals of Surgical Oncology, 2020, 27, 627-629.	1.5	3
43	Management of the clinically positive axilla. Breast Journal, 2020, 26, 35-38.	1.0	3
44	Choosing Bilateral Mastectomy. Breast Journal, 2016, 22, 605-606.	1.0	2
45	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. Journal of Human Genetics, 2017, 62, 379-387.	2.3	2
46	Breast Cancer Genetics. , 2018, , 237-249.e5.		2
47	Underutilization of Needle Biopsy Before Breast Surgery: A Measure of Low-Value Care. Annals of Surgical Oncology, 2021, 28, 2485-2492.	1.5	2
48	Legacy Genetic Testing Results for Cancer Susceptibility: How Common are Conflicting Classifications in a Large Variant Dataset from Multiple Practices?. Annals of Surgical Oncology, 2020, 27, 2212-2220.	1.5	1
49	Nipple-Sparing Mastectomy in Patients with Germline BRCA Mutations: Is it Safe?. Current Breast Cancer Reports, 2016, 8, 90-94.	1.0	0
50	Management of Rare Breast Tumors and Male Breast Cancer. Current Breast Cancer Reports, 2017, 9, 156-164.	1.0	0
51	Selecting the Right Tumors for Genomic Testing. Annals of Surgical Oncology, 2019, 26, 313-314.	1.5	0